Fig. 3From: Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkersPredicted differences in biomarker kinetics between neonates and adults, based on GFR, body size, and steady-state BBB function. The plot shown in (a) demonstrates, for steady-state S100B levels in blood, a ~16-fold increase for newborns compared to adults (0.92 and 0.055 ng/ml, respectively). After maximal BBBD, newborns presented a more dramatic increase in serum S100B concentrations. The horizontal dashed lines in (a) show a consistency between the observed levels and results from prior literature, for steady-state as well as maximal BBBD in adults [3, 24, 40]. Figure b and c show the behavior for serum levels of the homodimeric form of S100B (21 kD), as well as GFAP (26 kD) and S100B monomer. The concentration profiles in a newborn b show a significantly increased steady-state and post-BBBD serum level for all biomarkers, compared to an adult (c). The differences among markers within a neonatal or adult population was entirely attributed in our model to GFR values. The horizontal dashed lines in c again show consistency between model predictions and results from previous studies [3, 24, 40]Back to article page